… Current therapies for Parkinson's disease are symptomatic and unable to regenerate the
brain tissue. In recent years, the therapeutic potential of a wide variety of neuroprotective and …

… of substantia nigra neurons or disease progression of Parkinson's disease (PD). In addition,
… neurons and improved disease progression of the neurodegenerative diseases Alzheimer's …

… of Parkinson's disease pathogenesis … Parkinson's disease that are also aberrant in
sporadic cases. From this finding emerges a key concept regarding whether Parkinson's disease …

… The evidence for a role of apoptosis in the neurodegenerative diseases, Alzheimer's disease
(AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), and in the more …

… Application of nanomaterials in stem cell therapy of Parkinson’s disease. Preoperative …
addressing the limitations of cell-based therapy for Parkinson’s disease. Moreover, “intelligent” …

… In this review, we will discuss the prospects and challenges of hPSC-based cell therapy for
… Comparison of potential cell sources for cell replacement therapy for Parkinson’s disease (PD…

… 2016 International Parkinson and Movement Disorder Society Of all of the major
neurodegenerative diseases, Parkinson's disease (PD) has been demonstrated most clearly to have …

… We have proposed the term Parkinson's Disease at Risk Syndrome (PARS) to refer to
individuals who have markers that place them at a high risk for development of PD, but do not yet …

… progression of a disease as well as evaluating the response to disease-modifying treatments.
Currently, there is no biomarker fulfilling all such ideal criteria for Parkinson’s disease (PD)…

… Levodopa remains the most effective treatment for Parkinson's disease (PD). However, the
drug is complicated by a wide range of adverse effects, most notably motor fluctuations and …